BMS-345541

• UNSPSC Description:

  BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.

• Target Antigen:

  IKK

• Type:

  Reference compound

• Related Pathways:

  NF-κB

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BMS-345541-free-base.html

• Purity:

  99.86

• Solubility:

  DMSO : 10 mg/mL (ultrasonic)|H2O : 10 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21

• Molecular Weight:

  255.32

• References & Citations:

  [1]Burke JR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278(3), 1450-1456.|[2]Yang J, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res, 2006, 12(3 Pt 1), 950-960.|[3]MacMaster JF, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res, 2003, 52(12), 508-511.Aging (Albany NY). 2021 Aug 10;13(15):19088-19107.|Am J Hematol. 2024 Apr 22.|Am J Physiol Endocrinol Metab. 2021 Feb 15.|Biochem Biophys Res Commun. 2023 Nov 5, 680, Pages 127-134.|Biomed Pharmacother. 2020 Jul;127:110116.|Cancer Metab. 2024 Jul 8;12(1):20.|Front Microbiol. 2021 Feb 2;12:607451.|Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264.|iScience. 2024 May 16.|J Dent Res. 2019 Jul;98(8):896-903.|J Pharmacol Sci. 2023 Dec, 153(4), 188-196.|J Vet Sci. 2023 Sep 4;24(5):e72.|J Virol. 2019 Nov 26;93(24):e01499-19.|Nat Metab. 2023 Mar 6.|PLoS Comput Biol. 2020 Jun 26;16(6):e1007901.|Research Square Print. October 27th, 2022.|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.|Cancer Cell. 2015 Mar 9;27(3):409-25. |Cell Res. 2019 Mar;29(3):193-205. |Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Harvard Medical School LINCS LIBRARY|J Mol Med. 2020 Oct;98(10):1479-1491.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  445430-58-0